Amphetamine-Type Stimulants (Amphetamine, Dextroamphetamine, Methylphenidate & Modafinil)
Amphetamine-Type Stimulants (Amphetamine, Dextroamphetamine, Methylphenidate & Modafinil) is classified under Group B (Pharmacological & Prohibited Performance-Enhancing Substances). It is NOT recommended as an athletic performance aid. This monograph provides objective clinical pharmacology, toxicology, Indian statutory regulation, and WADA anti-doping education only—it never provides doping cycles, stacking regimens, or testing-evasion instructions. Any legitimate therapeutic use requires specialist medical diagnosis and supervision.
1. Generic or Accepted Substance Name & Classifications
Accepted Name: Amphetamine-Type Stimulants (Amphetamine, Dextroamphetamine, Methylphenidate & Modafinil)
Common Names, Synonyms & Classifications: Amphetamine; Dextroamphetamine; Lisdexamfetamine; Methylphenidate Hydrochloride IP; Modafinil; Armodafinil; 1,3-Dimethylamylamine (DMAA / Methylhexanamine)
Section Classification: Group B — Pharmacological & Prohibited Performance-Enhancing Substances (PERF-B16)
2. Pharmacological Class
Central Nervous System Psychostimulants; Catecholamine (Dopamine / Noradrenaline) Reuptake Inhibitors & Vesicular Releasers
3. Mechanism of Action
Amphetamines act as competitive substrates for the Dopamine Transporter (DAT) and Noradrenaline Transporter (NET) and inhibit Vesicular Monoamine Transporter 2 (VMAT2), reversing transporter flux to release synaptic dopamine and noradrenaline in the prefrontal cortex, striatum, and reticular activating system. Methylphenidate blocks DAT/NET reuptake without vesicular depletion; Modafinil weakly inhibits DAT and activates hypothalamic orexin/histaminergic wakefulness pathways.
4. Proposed Performance or Endurance Effects (Pharmacological Effect vs Proven Athletic Outcome)
Pharmacological Effect: Masks central fatigue, increases alertness, elevates heart rate/blood pressure, and suppresses appetite. Anti-Doping & Clinical Reality: Prohibited in-competition under WADA S6 because masking protective fatigue signals during maximal exertion in hot environments directly precipitates fatal exertional heatstroke, malignant arrhythmias, and cardiovascular collapse (historically responsible for high-profile cycling deaths).
5. Quality of Scientific Evidence
Evidence Assessment: PROHIBITED IN-COMPETITION STIMULANT CLASS (WADA S6) — High Risk of Exertional Heatstroke, Arrhythmia, Psychosis & Addiction
6. Approved Medical Uses (Where Applicable)
Methylphenidate Hydrochloride IP is a tightly regulated Schedule X / psychotropic medicine indicated strictly for diagnosed Attention-Deficit/Hyperactivity Disorder (ADHD) and narcolepsy under specialist psychiatric/neurological care; Modafinil is indicated for narcolepsy, obstructive sleep apnoea residual sleepiness, and shift-work disorder.
7. Sports-Related Uses, Misuse Patterns & Contamination Risks
Illicit in-competition use to mask fatigue, focus in esports/target sports, or suppress appetite for rapid weight cutting. Synthetic aliphatic amine stimulants such as Methylhexanamine (DMAA), DMBA, and Octodrine are frequently hidden in unregulated 'hardcore pre-workout' and 'fat-burner' supplements under deceptive botanical names ('geranium oil extract').
8. Adverse Effects & Serious Safety Risks
Tachycardia, severe systemic hypertension, coronary vasospasm, acute myocardial infarction, aortic dissection, fatal exertional hyperthermia/heatstroke (by impairing thermoregulatory perception and cutaneous vasodilation), rhabdomyolysis, acute paranoid psychosis, seizures, and haemorrhagic stroke.
9. Contraindications & Precautions
Cardiovascular disease, moderate-to-severe hypertension, hyperthyroidism, glaucoma, history of substance use disorder, agitation/psychosis, concurrent MAOI therapy (within 14 days), and non-medical athletic use.
10. Drug Interactions
Hypertensive crisis with Monoamine Oxidase Inhibitors (MAOIs, including Linezolid and Selegiline); additive sympathomimetic toxicity with decongestants, caffeine, or beta-agonists; Modafinil induces CYP3A4 (reducing effectiveness of steroidal oral contraceptives) and inhibits CYP2C19 (increasing Phenytoin/Diazepam levels).
11. Clinical & Laboratory Monitoring Considerations
In legitimate ADHD/narcolepsy patients: Baseline and periodic cardiovascular assessment (blood pressure, pulse), height/weight growth charts in paediatric patients, and psychiatric screening for mania or dependence. Athletes with diagnosed ADHD require a strictly documented WADA Therapeutic Use Exemption (TUE).
12. Dependence, Misuse or Withdrawal Concerns
High abuse and addiction liability (Schedule X / NDPS psychotropic controls). Abrupt cessation after chronic misuse causes a severe 'crash' characterised by hypersomnia, hyperphagia, psychomotor retardation, and severe depression.
13. Regulatory & Legal Status in India (CDSCO / Drugs Rules / NDPS / FSSAI)
Amphetamine and Methylphenidate are strictly controlled under Schedule X of the Drugs Rules, 1945 (requiring duplicate prescription retention for 2 years under lock and key) and the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985 in India. Modafinil is a Schedule H prescription drug.
14. Official WADA Prohibited-List Status
PROHIBITED IN-COMPETITION under WADA Prohibited List Category S6 (Stimulants: S6.A Non-Specified Stimulants [Amphetamine, Dextroamphetamine, Modafinil, Armodafinil] and S6.B Specified Stimulants [Methylphenidate, Methylhexanamine/DMAA, Pseudoephedrine >150 mcg/mL urinary threshold]).
15. Authoritative Source References & Date of Last Verification
Date of Last Verification: 11 November 2026